Yilong Wang
Clinical trials sponsored by Yilong Wang, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Skull injection could bypass brain barrier for stroke patients Results expected Nov 2026 (estimated)
- New drug trial hopes to slow rare brain disorder Results expected Jan 2027 (estimated)
- Can antibiotics dripped through the skull bone reach the brain better than IV drugs alone? Results expected Jan 2027 (estimated)
- Brain injection method could revolutionize meningitis treatment Results expected Apr 2027 (estimated)
-
Experimental protein therapy targets rare brain disease
Disease control Recruiting nowThis early-phase trial tests a drug called ALT001, a nerve repair protein, in 60 people with multiple system atrophy (MSA), a rare and progressive brain disorder. The study is open-label, meaning everyone knows they are getting the drug, and it focuses on safety and whether the d…
Early phase 1 • Sponsor: yilong Wang • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New drug trial hopes to slow rare brain disorder
Disease control Recruiting nowThis early-stage study tests a new drug, ALT001, in 20 people with a rare brain disease called multiple system atrophy-cerebellar type (MSA-C). The main goal is to check if the drug is safe and tolerable. Researchers will also look for early signs that it might help control the d…
Early phase 1 • Sponsor: yilong Wang • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC